Patents by Inventor Jason C. LONG

Jason C. LONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide PAC1 antagonists
    Patent number: 11643440
    Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 9, 2023
    Assignee: AMGEN INC.
    Inventors: Irwin Chen, Su Chong, Essa Hu Harrington, Fang-Tsao Hong, Jason C. Long, Leslie P. Miranda
  • RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION
    Publication number: 20220047621
    Abstract: The present invention relates to RNAi constructs for reducing expression of the MARC1 gene. Methods of using such RNAi constructs to treat or prevent liver fibrosis and fatty liver diseases, such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, are also described.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 17, 2022
    Applicant: AMGEN INC.
    Inventors: Justin K. MURRAY, Jun ZHANG, Oliver HOMANN, Jason C. LONG, Bryan MEADE
  • PEPTIDE PAC1 ANTAGONISTS
    Publication number: 20210395313
    Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 23, 2021
    Inventors: Irwin CHEN, Su CHONG, Essa Hu HARRINGTON, Fang-Tsao HONG, Jason C. LONG, Leslie P. MIRANDA
  • Potent and selective inhibitors of Nav1.7
    Patent number: 10344060
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 9, 2019
    Assignee: AMGEN INC.
    Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda, Kaustav Biswas, Bin Wu, Kelvin Sham, Jason C. Long
  • POTENT AND SELECTIVE INHIBITORS OF NAV1.7
    Publication number: 20160024159
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Applicant: AMGEN INC.
    Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA, Kaustav BISWAS, Bin WU, Kelvin SHAM, Jason C. LONG